TY - JOUR
T1 - Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network
AU - The eMERGE Consortium
AU - Zouk, Hana
AU - Venner, Eric
AU - Lennon, Niall J.
AU - Muzny, Donna M.
AU - Abrams, Debra
AU - Adunyah, Samuel
AU - Albertson-Junkans, Ladia
AU - Ames, Darren C.
AU - Appelbaum, Paul
AU - Aronson, Samuel
AU - Aufox, Sharon
AU - Babb, Lawrence J.
AU - Balasubramanian, Adithya
AU - Bangash, Hana
AU - Basford, Melissa
AU - Bastarache, Lisa
AU - Baxter, Samantha
AU - Behr, Meckenzie
AU - Benoit, Barbara
AU - Bhoj, Elizabeth
AU - Bielinski, Suzette J.
AU - Bland, Harris T.
AU - Blout, Carrie
AU - Borthwick, Kenneth
AU - Bottinger, Erwin P.
AU - Bowser, Mark
AU - Brand, Harrison
AU - Brilliant, Murray
AU - Brodeur, Wendy
AU - Caraballo, Pedro
AU - Carrell, David
AU - Carroll, Andrew
AU - Almoguera, Berta
AU - Castillo, Lisa
AU - Castro, Victor
AU - Chandanavelli, Gauthami
AU - Chiang, Theodore
AU - Chisholm, Rex L.
AU - Christensen, Kurt D.
AU - Chung, Wendy
AU - Chute, Christopher G.
AU - City, Brittany
AU - Cobb, Beth L.
AU - Connolly, John J.
AU - Crane, Paul
AU - Crew, Katherine
AU - Crosslin, David
AU - Gharavi, Ali
AU - Kenny, Eimear E.
AU - Scott, Stuart
N1 - Funding Information:
Samuel Aronson is employed at Partners HealthCare, which receives royalties on sales of GeneInsight Software. Samuel Aronson’s team receives funding from Sunquest and has received funding from Novartis for development of SMART on FHIR apps. Andrew Carroll is employed at Google Inc. and is a former employee of DNAnexus. Paul Crane served as a consultant to Eisai on efforts unrelated to this manuscript. David Crosslin serves on a consulting board for UnitedHealth Group with precision medicine efforts, which is unrelated to this manuscript. Christine Eng is a full-time employee/faculty member of Baylor College of Medicine. Through a professional services agreement, she serves as Chief Medical Officer and Chief Quality Officer of Baylor Genetics. Richard A. Gibbs declares that Baylor College of Medicine receives payments from Baylor Genetics Laboratories, which provides services for genetic testing; Baylor College of Medicine is part owner of Codified Genomics. Robert C. Green receives personal compensation from AIA, Applied Therapeutics, Helix, Prudential, Verily, and Veritas for speaking or consulting and is co-founder of Genome Medical, Inc. Eimear E. Kenny has received speaker honorariums from Illumina and Regeneron Pharmaceuticals. Niall J. Lennon is an advisor to Genturi Inc. Elizabeth McNally serves or has served as a consultant to Invitae, Tenaya, Exonics, Pfizer, AstraZeneca, Cytokinetics, and 4D Molecular Therapeutics and founded Ikaika Therapeutics. Thomas E. Mullen is employed at and a shareholder at Quest Diagnostics. Heidi Rehm is employed at Massachusetts General Hospital, which receives royalties on sales of GeneInsight Software. Avni Santani receives royalties from Agilent Technologies and a founder of Opus Genomics. Jordan W. Smoller is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe. Eric Venner is a cofounder of Codified Genomics. Theresa Walunas completed (in 2018) legal consulting for by Pfizer Inc., Wyeth LLC, Genetics Institute, LLC, Merck KGaA, and EMD Serono, Inc. Georgia L. Wiesner is a member of the External Advisory Panel for the ClinGen Clinical Genome Resource Project. Hana Zouk is employed at Massachusetts General Hospital which receives royalties on sales of GeneInsight Software.
Funding Information:
The eMERGE Phase III Network was initiated and funded by the National Human Genome Research Institute (NHGRI) through the following grants: U01HG8657 (Kaiser Permanente Washington Health Research Institute/University of Washington), U01HG8685 (Brigham and Women's Hospital), U01HG8672 (Vanderbilt University Medical Center), U01HG8666 (Cincinnati Children's Hospital Medical Center), U01HG6379 (Mayo Clinic), U01HG8679 (Geisinger Clinic), U01HG8680 (Columbia University Health Sciences), U01HG8684 (Children's Hospital of Philadelphia), U01HG8673 (Northwestern University), MD007593 (Meharry Medical College), U01HG8701 (Vanderbilt University Medical Center serving as the Coordinating Center), U01HG8676 (Partners Healthcare/Broad Institute), and U01HG8664 (Baylor College of Medicine).
Publisher Copyright:
© 2019 American Society of Human Genetics
PY - 2019/9/5
Y1 - 2019/9/5
N2 - The advancement of precision medicine requires new methods to coordinate and deliver genetic data from heterogeneous sources to physicians and patients. The eMERGE III Network enrolled >25,000 participants from biobank and prospective cohorts of predominantly healthy individuals for clinical genetic testing to determine clinically actionable findings. The network developed protocols linking together the 11 participant collection sites and 2 clinical genetic testing laboratories. DNA capture panels targeting 109 genes were used for testing of DNA and sample collection, data generation, interpretation, reporting, delivery, and storage were each harmonized. A compliant and secure network enabled ongoing review and reconciliation of clinical interpretations, while maintaining communication and data sharing between clinicians and investigators. A total of 202 individuals had positive diagnostic findings relevant to the indication for testing and 1,294 had additional/secondary findings of medical significance deemed to be returnable, establishing data return rates for other testing endeavors. This study accomplished integration of structured genomic results into multiple electronic health record (EHR) systems, setting the stage for clinical decision support to enable genomic medicine. Further, the established processes enable different sequencing sites to harmonize technical and interpretive aspects of sequencing tests, a critical achievement toward global standardization of genomic testing. The eMERGE protocols and tools are available for widespread dissemination.
AB - The advancement of precision medicine requires new methods to coordinate and deliver genetic data from heterogeneous sources to physicians and patients. The eMERGE III Network enrolled >25,000 participants from biobank and prospective cohorts of predominantly healthy individuals for clinical genetic testing to determine clinically actionable findings. The network developed protocols linking together the 11 participant collection sites and 2 clinical genetic testing laboratories. DNA capture panels targeting 109 genes were used for testing of DNA and sample collection, data generation, interpretation, reporting, delivery, and storage were each harmonized. A compliant and secure network enabled ongoing review and reconciliation of clinical interpretations, while maintaining communication and data sharing between clinicians and investigators. A total of 202 individuals had positive diagnostic findings relevant to the indication for testing and 1,294 had additional/secondary findings of medical significance deemed to be returnable, establishing data return rates for other testing endeavors. This study accomplished integration of structured genomic results into multiple electronic health record (EHR) systems, setting the stage for clinical decision support to enable genomic medicine. Further, the established processes enable different sequencing sites to harmonize technical and interpretive aspects of sequencing tests, a critical achievement toward global standardization of genomic testing. The eMERGE protocols and tools are available for widespread dissemination.
KW - clinical sequencing
KW - eMERGE
KW - electronic health record
KW - harmonization
KW - next generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85071493018&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2019.07.018
DO - 10.1016/j.ajhg.2019.07.018
M3 - Article
C2 - 31447099
AN - SCOPUS:85071493018
SN - 0002-9297
VL - 105
SP - 588
EP - 605
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 3
ER -